Today: 21 July 2026
Browse Category

NYSE:MRK 23 January 2026 - 7 February 2026

For live price, interactive charts, financials and the latest market data, visit Google Finance.
Dow Jones slips 167 points on AI disruption fears; Alphabet, Amazon earnings next

Dow Jones slips 167 points on AI disruption fears; Alphabet, Amazon earnings next

The Dow Jones Industrial Average dropped 166.67 points Tuesday, closing down 0.34% at 49,240.99 as tech and software stocks came under pressure amid renewed worries about AI squeezing profit margins. “We’re seeing a lot of software companies across the spectrum get hit,” said Art Hogan, chief market strategist at B. Riley Wealth. The S&P 500 fell 0.84% to 6,917.81, while the Nasdaq slid 1.43% to 23,255.19. Merck bucked the trend, rising 2.2% after reporting results, and PepsiCo surged 4.9% following announcements of price cuts on brands like Lay’s and Doritos.
3 February 2026
···········
Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Healthcare shares ended Friday stronger than the wider market following Eli Lilly’s announcement of a $3.5 billion manufacturing facility in Pennsylvania dedicated to injectable weight-loss drugs. CEO David Ricks described the new plant as “really state of the art manufacturing to last many decades to come” during a press briefing.
31 January 2026
······
Merck stock rises as markets wobble — what to watch before the Feb. 3 earnings call

Merck stock rises as markets wobble — what to watch before the Feb. 3 earnings call

Merck & Co shares climbed roughly 1.2% to $109.64 by Friday afternoon, finding footing after a volatile week for U.S. stocks. The health care sector showed strength, with the Health Care Select Sector SPDR ETF edging up about 0.6%, despite the broader market slide—the SPDR S&P 500 ETF dipped roughly 0.5%. Johnson & Johnson held steady, while Pfizer and Eli Lilly posted gains.
30 January 2026
···
Merck stock slips after report says MRK stepped back from Revolution Medicines talks

Merck stock slips after report says MRK stepped back from Revolution Medicines talks

Merck & Co shares slipped 0.6% to $107.57 in Monday afternoon trading after reports surfaced that the U.S. drugmaker ended talks to acquire cancer-drug developer Revolution Medicines. According to Reuters, which followed an initial report by the Wall Street Journal, negotiations stalled over price disagreements. The potential deal, valued between $28 billion and $32 billion, would have granted Merck access to Revolution’s late-stage drug daraxonrasib, carrying an FDA fast-track review voucher to speed up future approvals. Neither company has issued a comment.
26 January 2026
··
1 2 3 4 … 8
Go toTop